| 臺大學術典藏 |
2022-09-15T01:09:04Z |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
|
Shaw A.T.; Solomon B.J.; Chiari R.; Riely G.J.; Besse B.; Soo R.A.; Kao S.; Chia-Chi Lin; Bauer T.M.; Clancy J.S.; Thurm H.; Martini J.-F.; Peltz G.; Abbattista A.; Li S.; Ou S.-H.I. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S.; Shaw A.T.; Besse B.; Felip E.; Solomon B.J.; Soo R.A.; Bearz A.; Gadgeel S.M.; Chia-Chi Lin; Kao S.; Seto T.; Masters E.T.; Abbattista A.; Clancy J.S.; Thurm H.; Reisman A.; Peltz G.; Ross Camidge D. |
| 中山醫學大學 |
2021 |
Efficacy of Lorlatinib in Treatment-Naive Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations.
|
Bearz, A; Martini, JF; Jassem, J; Kim, SW; Chang, GC; Shaw, A; Shepard, D; Dall'O', E; Polli, A; Thurm, H; Zalcman, G; Campelo, MRG; Penkov, K; Hayashi, H; Solomon, BJ |
| 國立成功大學 |
2021 |
Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-na�ve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial
|
Adkins, D.R.;Lin, J.-C.;Sacco, A.;Ley, J.;Oppelt, P.;Vanchenko, Vanchenko V.;Komashko, N.;Yen, C.-J.;Wise-Draper, T.;Lopez-Picazo, Gonzalez J.;Radulovic, S.;Shen, Q.;Thurm, H.;Martini, J.-F.;Hoffman, J.;Huang, X.;Melichar, B.;Tahara, M. |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Impact of lorlatinib on patient-reported outcomes (PROs) in patients (Pts) with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC)
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgee S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Camidge D.R. |
| 臺大學術典藏 |
2020-05-25T07:35:08Z |
Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations
|
Solomon B.J; Martini J.-F; Ou S.-H.I; Chiari R; Soo R.A; Bearz A; Li S; Thurm H; Chia-Chi Lin; Riely G.J; Bauer T.M; Shaw A.T. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non�Vsmall-cell lung cancer
|
Shaw A.T; Solomon B.J; Besse B; Bauer T.M; Chia-Chi Lin; Soo R.A; Riely G.J; Ignatius Ou S.-H; Clancy J.S; Li S; Abbattista A; Thurm H; Satouchi M; Camidge D.R; Kao S; Chiari R; Gadgeel S.M; Felip E; Martini J.-F. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
|
Solomon B.J; Shaw A.T.; Ignatius Ou S.-H; Thurm H; Peltz G; Besse B; Bauer T.M; Felip E; Soo R.A; Camidge D.R; Chiari R; Bearz A; Chia-Chi Lin; Gadgeel S.M; Riely G.J; Tan E.H; Seto T; James L.P; Clancy J.S; Abbattista A; Martini J.-F; Chen J |
| 臺大學術典藏 |
2020-05-25T07:34:59Z |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
|
Peters S; Shaw A.T; Besse B; Felip E; Solomon B.J; Soo R.A; Bearz A; Gadgeel S.M; Chia-Chi Lin; Kao S; Seto T; Masters E.T; Abbattista A; Clancy J.S; Thurm H; Reisman A; Peltz G; Ross Camidge D. |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
| 臺大學術典藏 |
2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1�V2 trial
|
Ou S.-H.I.;Li S;Abbattista A;Peltz G;Martini J.-F;Thurm H;Clancy J.S;Bauer T.M;Chia-Chi Lin;Kao S;Soo R.A;Besse B;Riely G.J;Chiari R;Solomon B.J;Shaw A.T; Shaw A.T; Solomon B.J; Chiari R; Riely G.J; Besse B; Soo R.A; Kao S; Chia-Chi Lin; Bauer T.M; Clancy J.S; Thurm H; Martini J.-F; Peltz G; Abbattista A; Li S; Ou S.-H.I. |
